On February 2, 2021, the Korea Animal and Plant Quarantine Agency (APQA) has approved the New Drug Application for GNT Pharma's GedaCure^®, a chewable tablet of crisdesalazine, for the treatment of dogs with cognitive dysfunction syndrome (CDS).